Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: A Systematic Review
Open accessAbstract
BACKGROUND & AIMS: The incidence of inflammatory bowel diseases (IBD) is increasing in Latin America. We performed a systematic review to identify clinical and epidemiologic features of IBD in Latin America (including Mexico, Central America, and South America) and the Caribbean. METHODS: We searched MEDLINE, EMBASE, and SciELO databases for clinical or epidemiologic studies of Crohn's disease (CD) or ulcerative colitis (UC) from Latin American and Caribbean countries and territories that reported incidence, prevalence, ratio of UC:CD, IBD phenotype, and treatment, through September 12, 2018. Data were extracted from 61 articles for analysis. RESULTS: The incidence and prevalence of IBD have been steadily increasing in Latin America and the Caribbean. The incidence of CD in Brazil increased from 0.08 per 100,000 person-years in 1988 to 0.68 per 100,000 person-years in 1991-1995 to 5.5 per 100,000 person-years in 2015. The highest reported prevalence of IBD was in Argentina, in 2007, at 15 and 82 per 100,000 person-years for CD and UC, respectively. The ratio of UC:CD exceeded 1 in all regions throughout Latin America and the Caribbean with the exception of Brazil. Treatment with tumor necrosis factor antagonists increased steadily for patients with CD (43.4% of all patients in Brazil were treated in 2014) but less so for patients with UC (4.5% of all patients were treated in 2014). Surgery for IBD decreased with time. In Chile, surgeries were performed on 57.0% of patients with CD and 18.0% of patients with UC during the period of 1990-2002; these values decreased to 38.0% and 5.0%, respectively, during the period of 2012-2015. In Peru, 6.9% of patients with UC received colectomies in the period of 2001-2003 and 6.2% in 2004-2014. CONCLUSIONS: In a systematic review, we found the incidence of IBD to be increasing throughout Latin America and the Caribbean. Population-based epidemiology studies are needed to evaluate the increase in IBD in these regions, which differ from other global regions in climate, culture, demographics, diet, healthcare delivery and infrastructure, and socioeconomic status.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Published incidence figures from some areas of Brazil, China and India are near the Western-world Coalescing Incidence Range, such as 6-11 per 100,000 for ulcerative colitis.
“For example, some regions in Brazil, China and India already have published incidence values that are close to the Coalescing Incidence Range (for example, 6–11 per 100,000 for ulcerative colitis) in the Western world4,49,53,57.”
From The four epidemiological stages in the global evolution of inflammatory bowel disease (2021) · cites this paper as [49]
IBD diagnosis is skewed towards ulcerative colitis in lower income regions with limited technology, but as economies improve and health-care infrastructure develops, physicians can more accurately diagnose Crohn's disease.
“The diagnosis of IBD is skewed towards ulcerative colitis in lower income regions with limited technology (for example, access only to sigmoidoscopy); however, as economies improve, so too does health-care infrastructure (for example, access to specialists and colonoscopy), which improves the ability of physicians to accurately diagnose Crohn’s disease49.”
From The four epidemiological stages in the global evolution of inflammatory bowel disease (2021) · cites this paper as [49]
Historically, IBD typically emerges in a population as ulcerative colitis, followed later by Crohn's disease, and over time Crohn's disease becomes more commonly diagnosed as its incidence approximates or surpasses ulcerative colitis.
“Historically, IBD typically emerges in a population as cases of ulcerative colitis, eventually followed by cases of Crohn’s disease. Over time, Crohn’s disease becomes more commonly diagnosed as the incidence approximates and, in some cases, surpasses that of ulcerative colitis49.”
From The four epidemiological stages in the global evolution of inflammatory bowel disease (2021) · cites this paper as [49]
Prevalence remains low in most regions of Latin America.
“Similarly, prevalence remains low in most regions in Latin America.”
From The four epidemiological stages in the global evolution of inflammatory bowel disease (2021) · cites this paper as [49]
A systematic review of Latin American studies documented IBD emergence in the twentieth century with rapidly rising incidence during the twenty-first century.
“Moreover, a systematic review of clinical and epidemiological studies on IBD from Latin America documented the emergence of IBD in the twentieth century with a rapidly rising incidence during the twenty-first century49.”
From The four epidemiological stages in the global evolution of inflammatory bowel disease (2021) · cites this paper as [49]
The prevalent IBD population in newly industrialized Asian and Latin American countries is younger than the ageing Western IBD population.
“The prevalent IBD population in newly industrialized countries of Asia and Latin America have a younger age demographic as compared with the ageing IBD population of the Western world49.”
From The four epidemiological stages in the global evolution of inflammatory bowel disease (2021) · cites this paper as [49]
The citation lists haven’t been fetched yet
References 51 · Cited by 209
- Authors
- Kotze, P. G., Underwood, F. E., Damião, A. O. M. C., Ferraz, J. G. P., Saad-Hossne, R., Toro, M., Iade, B., Bosques-Padilla, F., Teixeira, F. V., Juliao-Banos, F., Simian, D., Ghosh, S., Panaccione, R., Ng, S. C., & Kaplan, G. G.
- Affiliations
- Pontifícia Universidade Católica do Paraná (BR)
- University of Calgary (CA)
- Hospital Maciel (UY)
- Clínica Las Condes (CL)
- Queen Elizabeth Hospital Birmingham (GB)
- Chinese University of Hong Kong (HK)
- Corresponding author
- Kotze, Paulo Gustavo
- Kaplan, Gilaad G.
- ORCID
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 18
- Issue
- 2
- Pages
- 304-312
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2954934400
- Cited by
- 209
- References
- 51
- Citations by year
- 2026: 26 · 2025: 25 · 2024: 19 · 2023: 41 · 2022: 33 · 2021: 35 · 2020: 29 · 2019: 1
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical Gastroenterology and Hepatology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- Gilead Sciences
- Canadian Institutes of Health Research (162393)
- AbbVie
- Shire
- Allergan
- Takeda Pharmaceutical Company
- GlaxoSmithKline
- UCB
- Pfizer
- Janssen Pharmaceuticals
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Epidemiology › Microscopic Colitis
- Keywords
- inflammatory bowel disease, Crohn's disease, ulcerative colitis, incidence, prevalence, Latin America, Caribbean, tumor necrosis factor inhibitors, IBD surgery, colectomy, IBD phenotypes, disease progression, Brazil, Argentina, Chile, Peru, Mexico, Central America, South America, treatment trends, surgical trends
- MeSH terms
- Colitis, Ulcerative, Crohn Disease, Humans, Latin America, Inflammatory Bowel Diseases, Incidence, Caribbean Region
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review